Indivior Pharmaceuticals (INDV) Pushes Cost Cuts And Growth, Is It Still 17% Undervalued?

Simply Wall St.06-26

Indivior Pharmaceuticals (INDV) continues to attract attention after its recent share price move, with the stock last closing at $41.29. See our latest analysis for Indivior Pharmaceuticals. Over the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2646981335?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-06-26 09:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646981335","market":"us","top_or_hot":-1,"title":"Indivior Pharmaceuticals (INDV) Pushes Cost Cuts And Growth, Is It Still 17% Undervalued?","media":"Simply Wall St.","content":"<div>\n<p>Indivior Pharmaceuticals (INDV) continues to attract attention after its recent share price move, with the stock last closing at $41.29. See our latest analysis for Indivior Pharmaceuticals. Over the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior-pharmaceuticals/news/indivior-pharmaceuticals-indv-pushes-cost-cuts-and-growth-is\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Indivior Pharmaceuticals (INDV) Pushes Cost Cuts And Growth, Is It Still 17% Undervalued?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndivior Pharmaceuticals (INDV) Pushes Cost Cuts And Growth, Is It Still 17% Undervalued?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-26 09:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior-pharmaceuticals/news/indivior-pharmaceuticals-indv-pushes-cost-cuts-and-growth-is><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Indivior Pharmaceuticals (INDV) continues to attract attention after its recent share price move, with the stock last closing at $41.29. See our latest analysis for Indivior Pharmaceuticals. Over the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior-pharmaceuticals/news/indivior-pharmaceuticals-indv-pushes-cost-cuts-and-growth-is\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior-pharmaceuticals/news/indivior-pharmaceuticals-indv-pushes-cost-cuts-and-growth-is","article_id":"2646981335","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior-pharmaceuticals/news/indivior-pharmaceuticals-indv-pushes-cost-cuts-and-growth-is","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2646981335","pubTimestamp":1782436773,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Indivior Pharmaceuticals (INDV) continues to attract attention after its recent share price move, with the stock last closing at $41.29.\nSee our latest analysis for Indivior Pharmaceuticals.\nOver the past year, Indivior Pharmaceuticals has shifted from short-term volatility to stronger momentum, with a 90-day share price return of 42.53% and a 1-year total shareholder return of 201.61% pointing to a significantly improved market perception of its prospects and risks.\nIf this kind of momentum...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","INDV":"INDIVIOR PLC"},"translate_title":"Indivior Pharmaceuticals(INDV)推动成本削减和增长，仍被低估17%吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INDV":1.5},"content_text":"Indivior Pharmaceuticals (INDV) continues to attract attention after its recent share price move, with the stock last closing at $41.29. See our latest analysis for Indivior Pharmaceuticals. Over the past year, Indivior Pharmaceuticals has shifted from short-term volatility to stronger momentum, with a 90-day share price return of 42.53% and a 1-year total shareholder return of 201.61% pointing to a significantly improved market perception of its prospects and risks. If this kind of momentum has you looking further across the market, it could be worth scanning the 39 healthcare AI stocks as a next step for new healthcare opportunities. With Indivior Pharmaceuticals posting a 1-year total shareholder return above 200% and trading at a discount to the average analyst price target, investors may be asking whether there is still a buying opportunity or if the market is already pricing in future growth. AdvertisementMost Popular Narrative: 17.4% Undervalued Against the last close at $41.29, the most followed narrative on Indivior Pharmaceuticals points to a fair value of $50.00, framing the recent price move as only part of the story.  The Indivior Action Agenda includes Phase 1, which is focused on simplifying the business, and Phase II, Accelerate, which is set to start in 2026. This plan is expected to reduce nonessential spend by at least US$150 million a year and cap 2026 operating expenses at US$450 million, which directly supports adjusted EBITDA growth and free cash flow.  Read the complete narrative. Want to see what sits behind that cost plan and fair value? The narrative leans heavily on earnings expansion, margin reset and a different profit multiple than today. Curious how those pieces connect to $50.00. Result: Fair Value of $50.00 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the Indivior Pharmaceuticals story could change quickly if long acting injectable adoption stalls, or if cost cuts begin to limit SUBLOCADE support and pipeline progress. Find out about the key risks to this Indivior Pharmaceuticals narrative. Next Steps If the mix of enthusiasm and caution around Indivior Pharmaceuticals has you thinking, do not wait too long to weigh both sides and test your own thesis with the 4 key rewards and 3 important warning signs. Looking for more investment ideas beyond Indivior Pharmaceuticals? If Indivior Pharmaceuticals has sharpened your focus, keep that momentum going by lining up a few more candidates so you are not relying on just one story.  Target companies that combine quality with a potential price gap by checking the 43 high quality undervalued stocks to see which stocks currently sit on investors' blind spot lists. Strengthen your income stream by scanning the 9 dividend fortresses and see which companies offer higher yields without ignoring balance sheet discipline. Sharpen your watchlist with resilient businesses by running through the 67 resilient stocks with low risk scores before the next wave of attention crowds into these ideas.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646981335","isCrawlerRequest":true}